Neurocrine Biosciences (NBIX) Earnings Analysis

Neurocrine Biosciences (NBIX) next reports earnings on 2026-07-30, consensus EPS 1.64 USD. Last quarter (2026-02-11) it beat with EPS 1.88 USD vs 1.8 USD est (+4.4%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E 25.74.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does NBIX next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate1.64 USD
Revenue estimate0.89B

NBIX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-111.88 USD1.8 USD+4.4%Beat
2025-07-301.06 USD0.98 USD+8.2%Beat
2025-05-050.08 USD0.535 USD-85%Miss
2025-02-061 USD1.62 USD-38.3%Miss
2024-08-010.63 USD1.05 USD-40%Miss

Beat rate: 2/5 (40%) over reported quarters with consensus data.

NBIX valuation and analyst view

Trailing P/E25.74
Trailing EPS6.653 USD
Price / book5.09
Dividend yield0.00%
Market cap17.61B
Analyst consensusBuy (32 buy / 5 hold / 0 sell)
Avg price target202.64 USD

Related research pages

Frequently asked questions

When is Neurocrine Biosciences (NBIX)'s next earnings date?

Neurocrine Biosciences is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 1.64 USD and revenue estimate of 0.89B.

Did NBIX beat earnings last quarter?

In its 2026-02-11 report, NBIX posted EPS of 1.88 USD versus a 1.8 USD estimate — a beat of 4.4%.

What is NBIX's earnings track record?

Over the last 5 reported quarters with consensus data, NBIX beat estimates 2 times (40%).

What is NBIX's current P/E ratio and EPS?

NBIX trades at a trailing P/E of 25.74 on trailing EPS of 6.65273631840796 USD.

What do analysts rate NBIX?

Analyst consensus is "Buy" across 37 ratings (0 strong buy, 32 buy, 5 hold, 0 sell, 0 strong sell). Average 12-month price target: 202.64 USD.